Solid Tumors (KiTu1)

Accredited Cancer Gene Panel (KiTu1) for Solid Tumor Analysis

The KiTu1 panel has been designed in collaboration with clinicians to cover, within a single panel, the most relevant gene alterations associated with a wide range of cancers.

The panel includes the following 53 genes:
ALK, ARID1A, ARID5B, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDK12, CDKN2A, CHEK1, CHEK2, CTNNB1, DICER1, EGFR, EPCAM, ERBB2, FANCL, FGFR2, FGFR3, KEAP1, KIT, KRAS, MET, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PDGFRA, PIK3CA, PMS2, POLE, PPP2R2A, PTEN, RAD50, RAD51B, RAD51C, RAD51D, RAD54L, RET, ROS1, SMARCA4, STK11, TP53.

For each gene, the analysis includes the protein-coding regions (exons) and 10 base pairs of intronic sequence on both sides of each exon (covering splice sites). The test detects DNA mutations in these regions. Variants identified include single nucleotide variants (SNVs) and small insertions or deletions, with a detection sensitivity of at least 5% variant allele frequency (VAF). In certain cases, pathogenic variants below 5% VAF may also be reported if sequencing depth is sufficient.

The KiTu1 panel is accredited for FFPE (formalin-fixed, paraffin-embedded) tumor tissue samples, but it can also be used to analyze germline mutations from blood samples.

Turnaround time: 10 working days from sample receipt
Price: €700 per sample